echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > A&R: Efficacy of a short-term bridging strategy with different doses of prednisolone on imaging and clinical outcomes in active early rheumatoid arthritis

    A&R: Efficacy of a short-term bridging strategy with different doses of prednisolone on imaging and clinical outcomes in active early rheumatoid arthritis

    • Last Update: 2022-08-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Purpose: In active early rheumatoid arthritis (RA) , glucocorticoids are often used for bridging due to the delayed effects of methotrexa.


    Purpose: In active early rheumatoid arthritis (RA) , glucocorticoids are often used for bridging due to the delayed effects of methotrexa.


    Methods: Adult RA patients with moderate / high disease activity from one rheumatology hospital and 23 rheumatology treatment centers were randomized (1:1:1) to 60 mg (high dose, HDP ) and 10 mg daily Prednisolone (low dose, LDP , tapering to 0 mg over 12 weeks ) or placeb.


    Methods: Adult RA patients with moderate / high disease activity from one rheumatology hospital and 23 rheumatology treatment centers were randomized (1:1:1) to 60 mg (high dose, HDP ) and 10 mg daily Prednisolone (low dose, LDP , tapering to 0 mg over 12 weeks ) or placeb.


    RESULTS: Of 395 randomized patients ( n=132 high-dose group, n=131 low-dose group, n=132 placebo), 375 ( 95% ) remained in the modified intention-to-treat analys.


    Conclusions: The results of this study showed that high-dose short-term glucocorticoid bridging (bridging) therapy did not have any benefit on the progression of radiographic damage in patients with rheumatoid arthritis within one ye.


    Krause,.
    , Mai,.
    , Klaassen-Mielke,.
    , et .
    (2022), The efficacy of short-term bridging strategies with high- and low-dose prednisolone on radiographic and clinical outcomes in active early rheumatoid arthritis : a double-blind, randomized, placebo-controlled tri.
    Arthritis Rheumat.
    Accepted Author Manuscri.
    https://d.
    org/11002/a.
    42245 Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.